Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria

Puntos clave

• The study aims to determine if ctDNA-derived tumor metrics improve risk stratification for HR-positive/HER2-negative advanced breast cancer.
• Conducted a multicenter cohort study across multiple institutions in Austria.
• Analyzed baseline ctDNA-derived tumor metrics alongside established clinical variables.
• Employed statistical methods to compare risk stratification improvements.
• Integration of ctDNA metrics significantly enhanced risk stratification.
• Improved accuracy in identifying patients at higher risk for disease progression.
• Demonstrated utility of ctDNA metrics in clinical decision-making for advanced breast cancer patients.